Dr Cascalló is an expert in oncolytic therapies and gene therapy, a field in which has been involved from his PhD. Author of many original scientific papers and reviews in peer-reviewed journals, he is co-inventor of 5 patents on the use of adenovirus as antitumoral agents. He has been a researcher at the University of Barcelona (Spain), at the MD. Anderson Cancer Center de Houston (Houston, USA), at Merck Farma y Química (Barcelona, Spain), and since 2001 at the Virotherapy Group of the Intitut Català d'Oncologia (ICO) – IDIBELL. During his professional career Dr. Cascalló has always been focused in the development of new biotechnological agents for cancer treatment where he has lead different multidisciplinary teams. He possesses a solid expertise in Regulatory Affairs in Gene Therapy and has acted as Expert for the European Medicines Agencies (EMA). Additionally Dr. Cascalló is Member of the Biosafety Committee at IDIBELL where he is actively involved in the supervision of research protocols and provides advice in biosafety-related issues. Dr. Cascalló has also received formation in the management of Biotechnological Companies by the University of Cambridge (UK), and posseses a solid basis in Executive Management by the internationally recognized IESE Business School.
financial and operational strategy, metrics and the development and monitoring of controlling